# Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Source: https://onco.cc/trials/nct06281964/  
OnCo record `nct06281964` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.

## Summary

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. is a phase 3, randomised interventional study registered as NCT06281964 by Avistone Biotechnology Co., Ltd., with a registry enrolment figure of 327 participants, started 2023-12-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: PLB1004; Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) by BICR. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: KANNON-2
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06281964
- Phase: 3
- Setting: Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of PLB1004 Versus Platinum-based Chemotherapy With or Without Sintilimab of Advanced NSCLC With EGFR Exon 20 Ins Mutations
- Sponsor: Avistone Biotechnology Co., Ltd.
- Enrolled: 327

## Sources

- ClinicalTrials.gov NCT06281964: https://clinicaltrials.gov/study/NCT06281964

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06281964.json